» Articles » PMID: 37961069

Neuroprotective Effects of Trigonelline in Kainic Acid-induced Epilepsy: Behavioral, Biochemical, and Functional Insights

Overview
Journal Saudi Pharm J
Specialty Pharmacy
Date 2023 Nov 14
PMID 37961069
Authors
Affiliations
Soon will be listed here.
Abstract

Trigonelline, an alkaloid found in the seeds of . (fenugreek), has been recognized for its potential in treating various diseases. Notably, trigonelline has demonstrated a neuroprotective impact by reducing intrasynaptosomal calcium levels, inhibiting the production of reactive oxygen species (ROS), and regulating cytokines. Kainic acid, an agonist of kainic acid receptors, is utilized for inducing temporal lobe epilepsy and is a common choice for establishing kainic acid-induced status epilepticus, a widely used epileptic model. The neuroprotective effect of trigonelline in the context of kainic acid-induced epilepsy remains unexplored. This study aimed to induce epilepsy by administering kainic acid (10 mg/kg, single subcutaneous dose) and subsequently evaluate the potential anti-epileptic effect of trigonelline (100 mg/kg, intraperitoneal administration for 14 days). Ethosuccimide (ETX) (187.5 mg/kg) served as the standard drug for comparison. The anti-epileptic effect of trigonelline over a 14-day administration period was examined. Behavioral assessments, such as the Novel Object Recognition (NOR) test, Open Field Test (OFT), and Plus Maze tests, were conducted 2 h after kainic acid administration to investigate spatial and non-spatial acquisition abilities in rats. Additionally, biochemical analysis encompassing intrasynaptosomal calcium levels, LDH activity, serotonin levels, oxidative indicators, and inflammatory cytokines associated with inflammation were evaluated. Trigonelline exhibited significant behavioral improvements by reducing anxiety in open field and plus maze tests, along with an amelioration of memory impairment. Notably, trigonelline substantially lowered intrasynaptosomal calcium levels and LDH activity, indicating its neuroprotective effect by mitigating cytotoxicity and neuronal injury within the hippocampus tissue. Moreover, trigonelline demonstrated a remarkable reduction in inflammatory cytokines and oxidative stress indicators. In summary, this study underscores the potential of trigonelline as an anti-epileptic agent in the context of kainic acid-induced epilepsy. The compound exhibited beneficial effects on behavior, neuroprotection, and inflammation, shedding light on its therapeutic promise for epilepsy management.

Citing Articles

Enhancement of Cognitive Function by Andrographolide-Loaded Lactose β-Cyclodextrin Nanoparticles: Synthesis, Optimization, and Behavioural Assessment.

Paramanick D, Rani K, Singh V, Basist P, Khan R, Al-Tamimi J Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065814 PMC: 11279429. DOI: 10.3390/ph17070966.


Trigonelline as an anticonvulsant agent: mechanistic insights into NMDA receptor expression and oxidative stress balance.

Kabiri-Samani N, Amini-Khoei H, Rahimi-Madiseh M, Sureda A, Lorigooini Z Sci Rep. 2024; 14(1):14239.

PMID: 38902338 PMC: 11189925. DOI: 10.1038/s41598-024-65301-z.


Pharmacological Activities, Therapeutic Effects, and Mechanistic Actions of Trigonelline.

Nguyen V, Taine E, Meng D, Cui T, Tan W Int J Mol Sci. 2024; 25(6).

PMID: 38542359 PMC: 10970276. DOI: 10.3390/ijms25063385.

References
1.
Theodore W, Spencer S, Wiebe S, Langfitt J, Ali A, Shafer P . Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia. 2006; 47(10):1700-22. DOI: 10.1111/j.1528-1167.2006.00633.x. View

2.
Liu L, Du X, Zhang Z, Zhou J . Trigonelline inhibits caspase 3 to protect β cells apoptosis in streptozotocin-induced type 1 diabetic mice. Eur J Pharmacol. 2018; 836:115-121. DOI: 10.1016/j.ejphar.2018.08.025. View

3.
Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

4.
Walsh R, Cummins R . The Open-Field Test: a critical review. Psychol Bull. 1976; 83(3):482-504. View

5.
Zhou J, Zhou S, Zeng S . Experimental diabetes treated with trigonelline: effect on β cell and pancreatic oxidative parameters. Fundam Clin Pharmacol. 2011; 27(3):279-87. DOI: 10.1111/j.1472-8206.2011.01022.x. View